Eric Rovner, MD, Urology, Mount Pleasant, SC, East Cooper Medical Center

EricSRovnerMD

Urology Mount Pleasant, SC

Female Urology/Pelvic Medicine & Reconstructive Surgery

Professor, Urology, Medical University of South Carolina College of Medicine

Dr. Rovner is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rovner's full profile

Already have an account?

Summary

  • Eric S. Rovner, M.D. is a Professor in the Department of Urology at the Medical University of South Carolina (MUSC) in Charleston, South Carolina. He is the director of the Section of Voiding Dysfunction, Female Urology and Urodynamics in the Department of Urology at MUSC. He has a highly specialized clinical practice within Urology and sees mostly patients with complex voiding problems including urinary incontinence, vaginal prolapse, urinary fistulae and neurogenic bladder dysfunction.

    He is a Board Certified member of the American Urological Association, Fellow of the American College of Surgeons, as well as a member of the Society of Pelvic Surgeons, Society of University Urologists, Societe Internationale D’Urologie, and the Society for Urodynamics and Female Urology (SUFU) among others. He is the President of SUFU. Dr. Rovner has served on several committees for the WHO International Consultation on Incontinence and has been a member of the AUA Urodynamics Guidelines Committee, and SUI Guidelines Committee. He has served on the AUA/ABU Exam Committee as well as the ABU Oral Exam Committee.

    Dr. Rovner’s research interests include the study of voiding dysfunction, overactive bladder, interstitial cystitis, neurourology and urodynamics. He has held several visiting professorships and is the author of numerous peer-reviewed scientific articles, monographs and book chapters on these topics as well as a book on urinary incontinence. He has been an invited speaker on numerous occasions throughout the United States and the world, and has been the Principal or co-investigator on multiple grants.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Urology, 1992 - 1996
  • University of Pennsylvania
    University of PennsylvaniaInternship, General Surgery, 1991 - 1992
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 1991

Certifications & Licensure

  • SC State Medical License
    SC State Medical License 2004 - 2023
  • NJ State Medical License
    NJ State Medical License 2002 - 2005
  • CA State Medical License
    CA State Medical License 1996 - 2023
  • PA State Medical License
    PA State Medical License 1993 - 2006
  • American Board of Urology Urology
  • American Board of Urology Female Pelvic Medicine and Reconstructive Surgery

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment  
    Alfred Kohan, Eric Rovner, Victor Nitti, The Journal of Urology
  • Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment  
    Eric Rovner, Victor Nitti, Alfred Kohan, The Journal of Urology

Lectures

  • Female Urology and Urogynecology Symposium 
    Quadrant HealthCom, Inc., Las Vegas, Nevada - 4/18/2013

Press Mentions

  • Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive Bladder
    Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive BladderFebruary 25th, 2020
  • Solace Therapeutics Says 3rd Trial of Vesair Bladder Device Met Endpoints
    Solace Therapeutics Says 3rd Trial of Vesair Bladder Device Met EndpointsMarch 1st, 2017

Professional Memberships

Hospital Affiliations